Alpine Immune Sciences Inc (NASDAQ:ALPN)
| 7.89 Delayed Data As of 12:00am ET |  +0.34 / +4.50%Today’s Change | 6.00 Today|||52-Week Range 15.14 | -43.03% Year-to-Date |
Latest ALPN News | Press Releases
| Alpine Immune Sciences, Inc. (ALPN) Reports Q1 Loss, Tops Revenue Estimates May 12 / Zacks.com - Paid Partner Content | Endo International (ENDP) Surpasses Q1 Earnings and Revenue Estimates May 05 / Zacks.com - Paid Partner Content |
| Ocular Therapeutix (OCUL) Reports Q1 Loss, Lags Revenue Estimates May 09 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 7.55 |
| Today’s open | 7.49 |
| Day’s range | 7.34 - 8.19 |
| Volume | 54,316 |
| Average volume (3 months) | 114,872 |
| Market cap | $229.5M |
Data as of 05/16/2022
Growth & Valuation
| Earnings growth (last year) | -47.26% |
| Earnings growth (this year) | +51.52% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +151.13% |
| P/E ratio | -- |
| Price/Sales | 15.05 |
| Price/Book | 1.89 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ADAPAdaptimmune Therapeu... | +0.01 | +0.71% |
| PSNLPersonalis Inc | -0.22 | -4.38% |
| JNCEJounce Therapeutics ... | +0.23 | +5.28% |
| ALTAltimmune Inc | -0.35 | -6.78% |
Data as of 05/16/2022
Financials
| Next reporting date | August 16, 2022 |
| EPS forecast (this quarter) | -$0.41 |
| Annual revenue (last year) | $23.4M |
| Annual profit (last year) | -$50.3M |
| Net profit margin | -214.70% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Seattle, Washington |
Forecasts
